Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Perrigo

This article was originally published in The Tan Sheet

Executive Summary

Private-label manufacturer appoints Mark Olesnavage, presently exec VP and chief operating officer for the firm's OTC business, to the new title of president-OTC pharmaceutical operations, effective Feb. 1. Olesnavage previously served as exec VP-sales and marketing and as VP-pharmaceutical business development. In the latter position, he is credited with developing Perrigo's Rx- to-OTC operations, which led to the marketing of private-label miconazole cream and loperamide
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS082407

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel